Administering drugs through slow intravenous (IV) drips rather than quick injections has long been a cumbersome and time-consuming process. However, a breakthrough in the form of a novel approach to the conventional spray drying technique offers a promising solution to make IV drug drips a thing of the past.
A significant challenge in the administration of protein-based pharmaceuticals, used to treat conditions like cancers, metabolic disorders, and autoimmune diseases, is the requirement for high dosage levels to achieve therapeutic efficacy. When dissolved in a carrier liquid for single-injection use at such high concentrations, these proteins tend to aggregate, resulting in a highly viscous mixture unsuitable for direct injection. Consequently, patients have to endure lengthy IV drip sessions spanning several hours.
Addressing this issue, Assoc. Prof. Eric Appel and his team at Stanford University introduced a biocompatible polyacrylamide copolymer named MoNi, distinguished by its remarkably high glass transition temperature. This unique property allows MoNi to maintain a solid and non-adhesive state at elevated temperatures, preventing protein aggregation.
The researchers combined MoNi with water and various therapeutic proteins, including albumin, human immunoglobulin, and a monoclonal antibody for COVID-19 treatment. Through aerosolization of this mixture into droplets followed by water evaporation, they successfully produced a fine powder comprising microscopic particles, each consisting of a protein core encapsulated by a smooth MoNi shell.
In the final phase of the process, the powder was mixed with a carrier liquid, enabling the microparticles to remain uniformly suspended without clumping. This innovative approach facilitated achieving protein concentrations exceeding 500 milligrams per milliliter, indicating that the liquid contained over 50% medication by weight, twice the concentration achievable with conventional injectable liquids.
Importantly, the resultant mixture exhibited suitable fluidity for smooth and easy injection, while the MoNi component was designed to dissolve upon entering the bloodstream. This transformative platform holds the potential for administering a wide range of biologic drugs with ease, shifting the paradigm from cumbersome clinic-based IV infusions lasting hours to convenient self-administration using autoinjectors at home.
The groundbreaking research detailing this novel drug preparation technique was recently published in the renowned journal Science Translational Medicine, underscoring its significance and potential impact on revolutionizing drug delivery methods.
- The innovative spray drying process offers a solution to the challenges associated with administering protein-based pharmaceuticals via IV drips.
- MoNi, a high glass transition temperature copolymer, prevents protein aggregation and enables high medication concentrations in carrier liquids.
- The new approach allows for easy and efficient single-injection drug delivery, transforming lengthy clinic-based infusion procedures into quick and convenient at-home self-administration.
- The research findings, published in Science Translational Medicine, highlight the potential of this platform to revolutionize drug administration methods.
Read more on newatlas.com